Journal of Clinical and Experimental Hematopathology

Scope & Guideline

Catalyzing Global Collaboration in Hematopathology.

Introduction

Welcome to the Journal of Clinical and Experimental Hematopathology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Journal of Clinical and Experimental Hematopathology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1346-4280
PublisherJAPANESE SOC LYMPHORETICULAR TISSUE RESEARCH
Support Open AccessYes
CountryJapan
TypeJournal
Convergefrom 2006 to 2016, from 2019 to 2024
AbbreviationJ CLIN EXP HEMATOP / J. Clin. Exp. Hematop.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressNAGOYA UNIV GRAD SCH MEDICINE, HIGH-TECHNOLOGY APPLICATION MEDICINE, CLINICAL PATHOPHYSI, NAGOYA 466-8550, JAPAN

Aims and Scopes

The Journal of Clinical and Experimental Hematopathology primarily focuses on advancing the understanding and treatment of hematologic malignancies. It serves as a platform for sharing innovative research findings, clinical experiences, and insights into the pathology of blood-related disorders, particularly lymphomas and leukemias.
  1. Hematologic Malignancies Research:
    The journal emphasizes research on various hematologic malignancies, including lymphomas, leukemias, and plasma cell disorders. It covers both clinical and experimental studies that contribute to the understanding of these diseases.
  2. Clinical Case Reports and Reviews:
    A significant portion of the journal includes case reports and literature reviews that provide insights into rare and complex cases, thereby enhancing clinical knowledge and guiding treatment strategies.
  3. Pathological Insights and Diagnostics:
    The journal highlights the importance of pathology in diagnosing hematologic disorders. It publishes studies focusing on histopathological evaluations, immunohistochemistry, and molecular techniques that assist in accurate diagnosis.
  4. Therapeutic Advances and Clinical Trials:
    Research on new therapeutic approaches, including novel drug treatments and clinical trial outcomes, is a core focus. The journal aims to disseminate findings that can influence treatment protocols and improve patient outcomes.
  5. Tumor Microenvironment and Immune Response:
    There is a growing emphasis on the role of the tumor microenvironment and immune interactions in hematologic diseases. The journal explores how these factors affect disease progression and treatment responses.
The Journal of Clinical and Experimental Hematopathology has been evolving, with several themes emerging as increasingly prominent in recent publications. This section outlines the trending and emerging scopes that reflect the current interests and advancements in the field.
  1. Precision Medicine and Targeted Therapies:
    There is a significant trend towards research focused on precision medicine and targeted therapies for hematologic malignancies. This includes studies on specific genetic mutations, biomarkers, and tailored treatment approaches that enhance efficacy and minimize toxicity.
  2. Immunotherapy and CAR T-cell Therapy:
    Immunotherapy, particularly CAR T-cell therapy, is gaining prominence in the journal's publications. Research exploring the mechanisms, efficacy, and safety of these therapies is increasingly relevant as they become standard treatment options for various hematologic cancers.
  3. Tumor Microenvironment Studies:
    Emerging themes related to the tumor microenvironment, including the interplay between tumor cells and immune cells, are becoming a focal point. This research is crucial for understanding disease progression and developing new therapeutic strategies.
  4. Patient-Centered Outcomes and Quality of Life:
    Research that addresses patient perspectives, treatment satisfaction, and quality of life is on the rise. This trend highlights the importance of incorporating patient-reported outcomes into clinical practice and research.
  5. Novel Biomarkers for Diagnosis and Prognosis:
    The discovery and validation of novel biomarkers for the diagnosis and prognosis of hematologic malignancies are increasingly featured. Such studies are essential for improving diagnostic accuracy and tailoring treatment strategies.

Declining or Waning

While the Journal of Clinical and Experimental Hematopathology maintains a broad focus on hematologic disorders, certain themes have begun to decline in prominence. This section highlights these waning scopes based on recent publication trends.
  1. Basic Laboratory Techniques:
    There appears to be a declining focus on basic laboratory techniques and methodologies compared to more advanced and specialized studies. Research that centers solely on traditional laboratory methods without novel insights or applications has become less common.
  2. Generalized Reviews without Novel Insights:
    The journal has seen a decrease in generalized review articles that do not provide new perspectives or significant updates on existing knowledge. There is a trend towards more focused reviews that address specific questions or emerging issues.
  3. Older Treatment Protocols:
    Research centered around older treatment protocols, especially those that have been largely replaced by newer regimens or therapies, is becoming less frequent. The journal is shifting towards studies that investigate contemporary treatment strategies and their outcomes.
  4. Epidemiological Studies without Clinical Relevance:
    Epidemiological studies that lack direct clinical relevance or applicability to current treatment practices are being published less frequently. The focus is moving towards studies that bridge the gap between epidemiology and clinical application.

Similar Journals

SEMINARS IN HEMATOLOGY

Connecting Scholars to Pioneering Hematological Research.
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0037-1963Frequency: 4 issues/year

SEMINARS IN HEMATOLOGY, published by W B SAUNDERS CO-ELSEVIER INC, stands as a premier academic journal dedicated to the field of hematology. Established in 1964, this journal has built a robust reputation over its nearly six-decade history, now recognized as a Q1 journal in Hematology with an impressive impact factor reflective of its high relevance and citation frequency within the academic community. Residents and scholars can access meticulously curated articles that address innovative research, clinical practices, and advancements in the understanding of blood disorders and treatment methodologies. The journal, ranked #36 out of 137 in the Scopus Medicine Hematology category, showcases cutting-edge research, ensuring its contributions are crucial for professionals, researchers, and students striving to stay at the forefront of the hematology field. Although not an Open Access journal, SEMINARS IN HEMATOLOGY continues to unite a global audience dedicated to advancing the science and clinical practices in hematology.

Indian Journal of Pathology and Microbiology

Illuminating the Frontiers of Pathological Research
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0377-4929Frequency: 4 issues/year

Indian Journal of Pathology and Microbiology, published by Wolters Kluwer Medknow Publications, is a distinguished open-access journal that has been fostering knowledge dissemination in the fields of pathology and microbiology since 2008. With an ISSN of 0377-4929 and E-ISSN 0974-5130, this journal serves as a critical resource for researchers and practitioners committed to advancing their understanding of medical sciences in India and beyond. Spanning decades of valuable research contributions since its establishment in 1972, it provides a platform for peer-reviewed articles that explore current trends and innovations in medicinal pathology and microbiological studies. Although it holds a Q4 ranking in categories such as medicine and microbiology, it maintains a notable Q3 classification in pathology and forensic medicine, highlighting its relevance to contemporary scientific discussions. Accessible freely to a global audience, the journal plays a pivotal role in enhancing scholarly communication and collaboration, making it an indispensable tool for students, professionals, and researchers alike aiming to contribute to this evolving discipline.

Hematology Reports

Unlocking the future of hematology research.
Publisher: MDPIISSN: 2038-8322Frequency: 4 issues/year

Hematology Reports is an esteemed academic journal in the field of hematology, dedicated to advancing the understanding of blood disorders and their treatment. Published by MDPI, a leading Swiss publisher known for its commitment to open access since 2009, this journal provides a valuable platform for researchers and healthcare professionals to disseminate innovative findings and foster collaboration within the academic community. The journal features an array of articles ranging from clinical studies to laboratory research, and is indexed in Scopus, where it currently holds a rank of 113 out of 137 in the Medicine - Hematology category, placing it in the 17th percentile. As an open-access journal, Hematology Reports ensures that critical research is accessible to a global audience, supporting the dissemination of knowledge that has the potential to improve patient outcomes. This journal is an essential resource for those engaged in the study and treatment of hematological conditions, encouraging dialogue and the exchange of ideas to enhance clinical practices.

Journal of Hematopathology

Fostering insights into blood-related diseases.
Publisher: SPRINGER HEIDELBERGISSN: 1868-9256Frequency: 4 issues/year

The Journal of Hematopathology, published by SPRINGER HEIDELBERG, serves as a vital resource in the fields of hematology, histology, and pathology. Established in 2008, this peer-reviewed journal aims to foster the exchange of knowledge among researchers, clinicians, and students by publishing original articles, reviews, and case studies that contribute to the understanding of hematopathological disorders. While the journal currently ranks in the fourth quartile in various categories including hematology and histology, it positions itself as a platform for emergent research and insights, addressing the evolving landscape of blood-related diseases. Although not an open access journal, it provides crucial access to research findings for professionals looking to stay abreast of developments in pathologic diagnostics and therapeutic strategies. As it continues to grow, the journal remains committed to enhancing the knowledge base and scientific discourse in hematopathology.

Rare Tumors

Connecting researchers to combat rare tumors.
Publisher: SAGE PUBLICATIONS LTDISSN: 2036-3605Frequency: 1 issue/year

Rare Tumors, published by SAGE Publications Ltd, is a premier open-access journal dedicated to advancing the understanding and research of rare neoplasms. With the ISSN 2036-3605 and E-ISSN 2036-3613, this journal provides a vital platform for sharing innovative research findings and clinical insights since its inception in 2009. Situated in Italy, Rare Tumors has a converged publication timeline from 2010 to 2024 and aims to foster a supportive community for researchers and professionals in the oncology and histology fields. It has achieved a notable Q3 ranking in Oncology and Q4 in Histology as of 2023, reflecting its crucial role in bridging the knowledge gap in these specialized areas. Despite its relatively humble Scopus ranks, the journal's open-access model ensures that vital information reaches a broad audience, including those in academia, clinical practice, and beyond. It aspires to not only document rare tumor cases but also stimulate dialogue on their diagnosis, treatment, and management strategies, making it an indispensable resource for anyone dedicated to tackling the challenges posed by rare tumors.

Experimental Hematology & Oncology

Transforming Research into Breakthroughs in Hematology & Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

Blood Cancer Discovery

Catalyzing Change in Cancer Research Landscapes
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

BLOOD

Pioneering Research at the Heart of Hematology.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Unveiling Innovations in Hematology
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

International Journal of Clinical and Experimental Pathology

Advancing Knowledge in Pathology and Beyond
Publisher: E-CENTURY PUBLISHING CORPISSN: 1936-2625Frequency: 12 issues/year

International Journal of Clinical and Experimental Pathology, published by E-CENTURY PUBLISHING CORP, serves as a vital resource for professionals in the field of pathology. With its ISSN 1936-2625, the journal has positioned itself within the competitive landscape of medical journals, achieving commendable rankings in Scopus, particularly in the categories of Pathology and Forensic Medicine (Rank #98/185) and Histology (Rank #38/58). Although its coverage in Scopus has been discontinued, the journal’s past contributions from 2009 to 2017 continue to be a touchstone for researchers interested in advancing their understanding of clinical and experimental pathology. The open-access format ensures accessibility to a wide audience, fostering collaboration and education in this essential medical discipline. By bridging clinical research and experimental findings, this journal plays a crucial role in disseminating knowledge and enhancing practices within pathology, making it an indispensable tool for researchers, professionals, and students alike.